Profile data is unavailable for this security.
About the company
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
- Revenue in USD (TTM)426.00k
- Net income in USD-88.45m
- Incorporated2005
- Employees59.00
- LocationAltimmune Inc910 Clopper Rd Ste 201SGAITHERSBURG 20878-1361United StatesUSA
- Phone+1 (240) 654-1450
- Fax+1 (302) 674-5266
- Websitehttps://altimmune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arbutus Biopharma Corp | 18.14m | -72.85m | 490.08m | 73.00 | -- | 4.36 | -- | 27.01 | -0.4386 | -0.4386 | 0.1093 | 0.6241 | 0.1068 | -- | 11.60 | 248,506.80 | -42.88 | -52.62 | -51.22 | -58.11 | -- | -- | -401.57 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -62.74m | 496.68m | 129.00 | -- | -- | -- | -- | -1.68 | -1.68 | 0.00 | -6.83 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -3.73 | -- | -- | -- |
| Absci Corp | 5.72m | -110.57m | 502.46m | 155.00 | -- | 2.35 | -- | 87.87 | -1.20 | -1.20 | 0.0621 | 1.89 | 0.0212 | -- | 3.06 | 36,890.32 | -41.08 | -- | -46.22 | -- | -- | -- | -1,933.65 | -- | -- | -93.25 | 0.0467 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Exscientia PLC (ADR) | 25.12m | -182.64m | 503.22m | 483.00 | -- | 1.13 | -- | 20.03 | -1.45 | -1.45 | 0.1999 | 3.54 | 0.0346 | 1,096.08 | 9.86 | 52,018.25 | -25.16 | -- | -29.09 | -- | -36.47 | -- | -726.94 | -- | 6.22 | -- | 0.0505 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Astria Therapeutics Inc | 0.00 | -72.89m | 503.46m | 59.00 | -- | 2.55 | -- | -- | -2.34 | -2.34 | 0.00 | 5.92 | 0.00 | -- | -- | 0.00 | -30.04 | -64.48 | -31.37 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Phibro Animal Health Corp | 982.01m | 14.80m | 503.86m | 1.92k | 34.05 | 1.86 | 10.15 | 0.5131 | 0.3654 | 0.3654 | 24.24 | 6.69 | 1.02 | 2.37 | 6.49 | 511,465.60 | 1.53 | 5.46 | 1.87 | 6.83 | 30.43 | 31.41 | 1.51 | 5.11 | 1.60 | 2.50 | 0.6369 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
| SNDL Inc | 665.69m | -123.12m | 507.96m | 2.52k | -- | 0.5773 | -- | 0.763 | -0.4727 | -0.4854 | 2.57 | 3.38 | 0.5995 | 5.29 | 36.58 | 264,584.50 | -11.34 | -24.44 | -12.28 | -27.94 | 24.17 | 22.49 | -18.92 | -62.17 | 2.69 | -9.29 | 0.1196 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| Altimmune Inc | 426.00k | -88.45m | 510.45m | 59.00 | -- | 2.62 | -- | 1,198.23 | -1.64 | -1.64 | 0.008 | 2.75 | 0.002 | -- | 0.6636 | 7,220.34 | -42.36 | -39.62 | -45.55 | -42.58 | -- | -- | -20,762.21 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| AnaptysBio Inc | 17.16m | -163.62m | 515.50m | 117.00 | -- | 5.70 | -- | 30.05 | -6.07 | -6.07 | 0.6372 | 3.31 | 0.0323 | -- | 4.15 | 146,641.00 | -30.79 | -18.08 | -32.75 | -18.96 | -- | -- | -953.66 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Prime Medicine Inc | 0.00 | -198.13m | 515.74m | 234.00 | -- | 3.15 | -- | -- | -2.17 | -2.17 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -84.13 | -- | -- | -- | -- | -- | -- | -85.97 | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -100.70m | 516.77m | 100.00 | -- | 1.88 | -- | -- | -1.97 | -1.97 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -40.34 | -33.92 | -43.47 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| OmniAB Inc | 34.16m | -50.62m | 518.87m | 106.00 | -- | 1.65 | -- | 15.19 | -0.4986 | -0.4986 | 0.3292 | 2.69 | 0.0858 | -- | 2.00 | 322,301.90 | -12.71 | -- | -13.55 | -- | -- | -- | -148.16 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Verve Therapeutics Inc | 11.76m | -200.07m | 520.11m | 255.00 | -- | 0.8505 | -- | 44.23 | -3.13 | -3.13 | 0.1832 | 7.31 | 0.0164 | -- | 3.40 | 46,109.80 | -27.94 | -- | -29.43 | -- | -- | -- | -1,701.55 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Arrivent Biopharma Inc | 0.00 | -69.33m | 520.49m | 40.00 | -- | -- | -- | -- | -2.17 | -2.17 | 0.00 | 4.73 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Altimmune Inc's reporting currency: US Dollar USD
56.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 8.65m | 16.10% |
| Threadneedle Asset Management Ltd.as of 31 Dec 2023 | 4.01m | 7.47% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 3.76m | 6.99% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 3.53m | 6.57% |
| Millennium Management LLCas of 26 Feb 2024 | 2.91m | 5.42% |
| Tang Capital Management LLCas of 31 Dec 2023 | 2.75m | 5.12% |
| TIAA-CREF Investment Management LLCas of 31 Dec 2023 | 1.55m | 2.88% |
| Point72 Asset Management LPas of 31 Dec 2023 | 1.25m | 2.32% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.19m | 2.22% |
| Timelo Investment Management, Inc.as of 31 Dec 2023 | 809.10k | 1.51% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
